RGRX — RegeneRx Biopharmaceuticals Share Price
Last trade - 00:00- $0.00m
- $1.33m
- $0.08m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -1775.74% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | n/a | n/a | 6.26% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
RegeneRx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4 (TB4), for tissue and organ protection, repair, and regeneration. The Company has formulated TB4 into three distinct product candidates in clinical development: RGN-259, RGN-352 and RGN-137. RGN-259 is a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology. RGN-259 is in phase three clinical trials in the United States and EU for the treatment of neurotrophic keratitis, an orphan indication. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, organ damage associated with COVID-19, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue. It has active partnerships in four territories: North America, Europe, China and Pan Asia.
Directors
- Allan Goldstein CHM (83)
- J. Finkelstein PRE (69)
- Alessandro Noseda DRC (62)
- Mauro Bove IND (65)
- Raymond Elsey IND (67)
- Joseph Mcnay IND (87)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- May 13th, 1982
- Public Since
- December 23rd, 1986
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 1,496,966
- Address
- 15245 SHADY GROVE ROAD, SUITE 470, ROCKVILLE, 20850
- Web
- https://www.regenerx.com/
- Phone
- +1 3012089191
- Auditors
- CohnReznick LLP
Upcoming Events for RGRX
Similar to RGRX
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 16:54 UTC, shares in RegeneRx Biopharmaceuticals are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in RegeneRx Biopharmaceuticals last closed at $0.00 and the price had moved by -85.71% over the past 365 days. In terms of relative price strength the RegeneRx Biopharmaceuticals share price has underperformed the S&P500 Index by -86.75% over the past year.
There is no consensus recommendation for this security.
Find out moreRegeneRx Biopharmaceuticals does not currently pay a dividend.
RegeneRx Biopharmaceuticals does not currently pay a dividend.
RegeneRx Biopharmaceuticals does not currently pay a dividend.
To buy shares in RegeneRx Biopharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in RegeneRx Biopharmaceuticals had a market capitalisation of $0.00m.
Here are the trading details for RegeneRx Biopharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: RGRX
Based on an overall assessment of its quality, value and momentum RegeneRx Biopharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like RegeneRx Biopharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -85.68%.
As of the last closing price of $0.00, shares in RegeneRx Biopharmaceuticals were trading -99.99% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The RegeneRx Biopharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
RegeneRx Biopharmaceuticals' management team is headed by:
- Allan Goldstein - CHM
- J. Finkelstein - PRE
- Alessandro Noseda - DRC
- Mauro Bove - IND
- Raymond Elsey - IND
- Joseph Mcnay - IND